AnaptysBio Analyst Ratings
AnaptysBio Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/03/2023 | 16.51% | Wedbush | $18 → $20 | Maintains | Neutral |
11/02/2023 | 22.33% | UBS | $28 → $21 | Maintains | Neutral |
08/08/2023 | 51.46% | Wedbush | $29 → $26 | Maintains | Neutral |
05/22/2023 | 74.76% | JP Morgan | $31 → $30 | Upgrades | Underweight → Neutral |
05/12/2023 | 68.94% | Wedbush | → $29 | Reiterates | Neutral → Neutral |
05/12/2023 | 162.15% | Guggenheim | $44 → $45 | Maintains | Buy |
04/12/2023 | 80.59% | JP Morgan | $32 → $31 | Maintains | Underweight |
01/06/2023 | — | Raymond James | Downgrades | Outperform → Market Perform | |
11/18/2022 | 86.42% | JP Morgan | $24 → $32 | Maintains | Underweight |
11/09/2022 | 121.37% | Raymond James | $30 → $38 | Maintains | Outperform |
11/01/2022 | — | Guggenheim | Upgrades | Neutral → Buy | |
09/19/2022 | 103.89% | HC Wainwright & Co. | → $35 | Assumes | → Buy |
09/13/2022 | 63.11% | Truist Securities | $50 → $28 | Downgrades | Buy → Hold |
09/01/2022 | 103.89% | Raymond James | → $35 | Initiates Coverage On | → Outperform |
03/22/2022 | — | Guggenheim | Downgrades | Buy → Neutral | |
03/08/2022 | 167.97% | HC Wainwright & Co. | $43 → $46 | Maintains | Buy |
06/22/2021 | 150.5% | HC Wainwright & Co. | → $43 | Initiates Coverage On | → Buy |
05/21/2021 | 68.94% | UBS | → $29 | Initiates Coverage On | → Neutral |
03/16/2021 | 98.07% | Truist Securities | $27 → $34 | Upgrades | Hold → Buy |
03/09/2021 | — | Wedbush | Downgrades | Outperform → Neutral | |
02/11/2021 | 133.02% | JP Morgan | $19 → $40 | Upgrades | Underweight → Overweight |
10/27/2020 | 103.89% | Wedbush | $20 → $35 | Upgrades | Neutral → Outperform |
10/14/2020 | 109.72% | Guggenheim | → $36 | Upgrades | Neutral → Buy |
05/07/2020 | -6.79% | Credit Suisse | $14 → $16 | Maintains | Neutral |
03/03/2020 | -18.44% | SunTrust Robinson Humphrey | $15 → $14 | Maintains | Hold |
11/08/2019 | — | Guggenheim | Downgrades | Buy → Neutral | |
10/03/2019 | 179.62% | Credit Suisse | $75 → $48 | Maintains | Neutral |
08/09/2019 | 336.91% | Credit Suisse | $79 → $75 | Maintains | Neutral |
06/24/2019 | 441.77% | SunTrust Robinson Humphrey | $125 → $93 | Maintains | Buy |
06/21/2019 | — | Credit Suisse | Downgrades | Outperform → Neutral | |
02/22/2019 | — | Guggenheim | Initiates Coverage On | → Buy | |
12/20/2018 | 634.01% | HC Wainwright & Co. | → $126 | Initiates Coverage On | → Buy |
11/21/2018 | 569.93% | JP Morgan | → $115 | Initiates Coverage On | → Overweight |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
11/03/2023 | 16.51% | Wedbush | 18 美元 → 20 美元 | 维护 | 中立 |
11/02/2023 | 22.33% | 瑞银(UBS) | 28 美元 → 21 美元 | 维护 | 中立 |
08/08/2023 | 51.46% | Wedbush | 29 美元 → 26 美元 | 维护 | 中立 |
05/22/2023 | 74.76% | 摩根大通 | 31 美元 → 30 美元 | 升级 | 体重不足 → 中性 |
05/12/2023 | 68.94% | Wedbush | → 29 美元 | 重申 | 中性 → 中性 |
05/12/2023 | 162.15% | 古根海姆 | 44 美元 → 45 美元 | 维护 | 买 |
2023 年 12 月 4 日 | 80.59% | 摩根大通 | 32 美元 → 31 美元 | 维护 | 体重不足 |
01/06/2023 | — | 雷蒙德·詹姆 | 降级 | 跑赢大盘 → 市场表现 | |
11/18/2022 | 86.42% | 摩根大通 | 24 美元 → 32 美元 | 维护 | 体重不足 |
11/09/2022 | 121.37% | 雷蒙德·詹姆 | 30 美元 → 38 美元 | 维护 | 跑赢大盘 |
11/01/2022 | — | 古根海姆 | 升级 | 中性 → 买入 | |
09/19/2022 | 103.89% | HC Wainwright & Co. | → 35 美元 | 假设 | → 购买 |
09/13/2022 | 63.11% | Truist 证券 | 50 美元 → 28 美元 | 降级 | 买入 → 持有 |
2022 年 1 月 9 日 | 103.89% | 雷蒙德·詹姆 | → 35 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
03/22/2022 | — | 古根海姆 | 降级 | 买入 → 中性 | |
03/08/2022 | 167.97% | HC Wainwright & Co. | 43 美元 → 46 美元 | 维护 | 买 |
06/22/2021 | 150.5% | HC Wainwright & Co. | → 43 美元 | 启动覆盖范围开启 | → 购买 |
05/21/2021 | 68.94% | 瑞银(UBS) | → 29 美元 | 启动覆盖范围开启 | → 中立 |
03/16/2021 | 98.07% | Truist 证券 | 27 美元 → 34 美元 | 升级 | 持有 → 买入 |
2021 年 9 月 3 日 | — | Wedbush | 降级 | 跑赢大盘 → 中性 | |
2021 年 11 月 2 日 | 133.02% | 摩根大通 | 19 美元 → 40 美元 | 升级 | 体重过轻 → 超重 |
10/27/2020 | 103.89% | Wedbush | 20 美元 → 35 美元 | 升级 | 中性 → 跑赢大盘 |
2020 年 10 月 14 日 | 109.72% | 古根海姆 | → 36 美元 | 升级 | 中性 → 买入 |
05/07/2020 | -6.79% | 瑞士信贷 | 14 美元 → 16 美元 | 维护 | 中立 |
2020 年 3 月 3 日 | -18.44% | SunTrust 罗宾逊·汉弗莱 | 15 美元 → 14 美元 | 维护 | 保持 |
11/08/2019 | — | 古根海姆 | 降级 | 买入 → 中性 | |
10/03/2019 | 179.62% | 瑞士信贷 | 75 美元 → 48 美元 | 维护 | 中立 |
08/09/2019 | 336.91% | 瑞士信贷 | 79 美元 → 75 美元 | 维护 | 中立 |
06/24/2019 | 441.77% | SunTrust 罗宾逊·汉弗莱 | 125 美元 → 93 美元 | 维护 | 买 |
06/21/2019 | — | 瑞士信贷 | 降级 | 跑赢大盘 → 中性 | |
02/22/2019 | — | 古根海姆 | 启动覆盖范围开启 | → 购买 | |
2018 年 12 月 20 日 | 634.01% | HC Wainwright & Co. | → 126 美元 | 启动覆盖范围开启 | → 购买 |
11/21/2018 | 569.93% | 摩根大通 | → 115 美元 | 启动覆盖范围开启 | → 超重 |
What is the target price for AnaptysBio (ANAB)?
AnaptysBio(ANAB)的目标价格是多少?
The latest price target for AnaptysBio (NASDAQ: ANAB) was reported by Wedbush on November 3, 2023. The analyst firm set a price target for $20.00 expecting ANAB to rise to within 12 months (a possible 16.51% upside). 10 analyst firms have reported ratings in the last year.
Wedbush于2023年11月3日公布了AnaptysBio(纳斯达克股票代码:ANAB)的最新目标股价。该分析公司将目标股价定为20.00美元,预计ANAB将在12个月内升至12个月内(可能上涨16.51%)。去年有10家分析公司公布了评级。
What is the most recent analyst rating for AnaptysBio (ANAB)?
分析师对AnaptysBio(ANAB)的最新评级是多少?
The latest analyst rating for AnaptysBio (NASDAQ: ANAB) was provided by Wedbush, and AnaptysBio maintained their neutral rating.
AnaptysBio(纳斯达克股票代码:ANAB)的最新分析师评级由Wedbush提供,AnaptysBio维持中性评级。
When is the next analyst rating going to be posted or updated for AnaptysBio (ANAB)?
AnaptysBio(ANAB)的下一个分析师评级何时公布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AnaptysBio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AnaptysBio was filed on November 3, 2023 so you should expect the next rating to be made available sometime around November 3, 2024.
分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与AnaptysBio的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月做一次这样的评级,因此每家公司每年应该获得4次评级。AnaptysBio的最新评级是在2023年11月3日公布的,因此您应该预计下一个评级将在2024年11月3日左右公布。
Is the Analyst Rating AnaptysBio (ANAB) correct?
分析师对AnaptysBio(ANAB)的评级正确吗?
While ratings are subjective and will change, the latest AnaptysBio (ANAB) rating was a maintained with a price target of $18.00 to $20.00. The current price AnaptysBio (ANAB) is trading at is $17.17, which is out of the analyst's predicted range.
尽管评级是主观的,并且会发生变化,但最新的AnaptysBio(ANAB)评级维持不变,目标股价为18.00美元至20.00美元。AnaptysBio(ANAB)目前的交易价格为17.17美元,超出了分析师的预期区间。